Evidence map›Paper›PMID 35429319›Full record

ArticlePulmonary therapy2022

Quality of Life and Healthcare Resource Use in a Real-world Patient Population with Idiopathic Pulmonary Fibrosis: The PROOF Registry.

Wim A Wuyts, Caroline Dahlqvist, Hans Slabbynck, Marc Schlesser, Natacha Gusbin, Christophe Compere, Sofie Maddens, Shemra Rizzo, Klaus-Uwe Kirchgaessler, Karen Bartley and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pulmonary therapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 3 pooled it
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 3 syntheses or guidelines pooled it, 9 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 8 institutions in 2 countries.

Wim A WuytsDepartment of Respiratory Medicine, Unit for Interstitial Lung Diseases, University Hospitals Leuven, Herestraat 49, 3000, Leuven, Belgium. wim.wuyts@uzleuven.be.ORCID http://orcid.org/0000-0001-9648-3497
Caroline DahlqvistCHU UCL Namur Site Godinne, Yvoir, Belgium.
Hans SlabbynckDepartment of Respiratory Medicine, ZNA Middelheim, Antwerp, Belgium.
Marc SchlesserDepartment of Respiratory Care, Hôpitaux Robert Schuman, Luxembourg City, Luxembourg.
Natacha GusbinCHR de la Citadelle, Liege, Belgium.
Christophe CompereCHIREC Hospital, Brussels, Belgium.
Sofie MaddensAZ Groeninge, Kortrijk, Belgium.
Shemra RizzoGenentech, Inc., South San Francisco, CA, USA.
Klaus-Uwe KirchgaesslerF. Hoffmann-La Roche, Ltd., Basel, Switzerland.
Karen BartleyGenentech, Inc., South San Francisco, CA, USA.
Benjamin BondueDepartment of Respiratory Medicine, Erasme University Hospital, Brussels, Belgium.
AZ Groeninge · BECentre Hospitalier Interrégional Edith Cavell · BECentre hospitalier régional de la Citadelle · BECHU Dinant Godinne UCL Namur · BEErasmus Hospital · BEKU Leuven · BERoche (Switzerland) · CHZNA Middelheim Hospital · BE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThe PROOF registry is a prospective, observational study that aimed to monitor disease progression in a real-world cohort of patients with idiopathic pulmonary fibrosis (IPF). Here, longitudinal quality-of-life (QoL) outcomes, healthcare resource use (HCRU), and the association between QoL and mortality in patients enrolled in the PROOF registry are presented.

methodsQoL outcomes (St. George's Respiratory Questionnaire [SGRQ], EuroQoL-5 dimensions-5 levels Health Questionnaire [EQ-5D-5L], EuroQoL-5 dimensions Health Questionnaire [EQ-5D] visual analogue scale [VAS] and cough VAS) and HCRU were collected for all patients. Associations between baseline QoL and mortality were assessed using univariate and multivariate analyses. During multivariate analyses, individual QoL measures were adjusted for the following covariates: age, sex, percent predicted forced vital capacity, percent predicted diffusing capacity of the lungs for carbon monoxide, smoking status, and supplementary oxygen use at registry inclusion.

resultsIn total, 277 patients were enrolled in the PROOF registry. During the follow-up period, worsening in cough VAS score, SGRQ symptom score, and SGRQ activity score was observed, while EQ-5D VAS, SGRQ total score, and SGRQ impact score remained stable. During univariate analyses, EQ-5D VAS and all SGRQ sub-scores and total score at baseline were associated with mortality; however, during multivariate analyses, only the SGRQ total score, SGRQ impact score, and SGRQ symptom score at baseline were associated with mortality. During the follow-up period, 261 (94.2%) patients required an outpatient consultation (IPF- or non-IPF-related) and there were 182 hospitalizations in total, most of which were respiratory related (66.5%).

conclusionsThe PROOF registry provided valuable, real-world data on the association between baseline QoL and mortality, and longitudinal HCRU and QoL outcomes in patients with IPF over 24 months and identified that SGRQ may be an independent prognostic factor in IPF.

Indexed as

Healthcare resource useIdiopathic pulmonary fibrosisMortalityMultivariate analysisPatient registryQuality of lifeReal worldUnivariate analysis

Identifiers

PMID35429319
PMCPMC9098727
OpenAlexW4224063331

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.